RxSight, Inc.

Informe acción NasdaqGM:RXST

Capitalización de mercado: US$2.3b

Salud financiera de hoja de balance de RxSight

Salud financiera controles de criterios 5/6

RxSight tiene un patrimonio de los accionistas total de $160.4M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $182.6M y $22.2M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$125.35m
PatrimonioUS$163.93m
Total pasivoUS$19.24m
Activos totalesUS$183.17m

Actualizaciones recientes sobre salud financiera

Recent updates

RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results

May 09
RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results

RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business

May 05
RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business

RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation

May 01

Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price

Apr 16
Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price

Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?

Mar 24
Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?

RxSight Stock: Time To Refocus Following Eye Watering Rally

Jan 16

RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

Jan 09
RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth

Dec 21
We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth

Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%

Nov 24
Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%

RxSight, Inc. (NASDAQ:RXST) Just Reported And Analysts Have Been Lifting Their Price Targets

Aug 11
RxSight, Inc. (NASDAQ:RXST) Just Reported And Analysts Have Been Lifting Their Price Targets

RxSight Non-GAAP EPS of -$0.50 beats by $0.15, revenue of $11.4M beats by $0.85M

Aug 08

RxSight says FDA requires additional info for approval of light delivery device

Jul 12

RxSight: First And Only Customizable Intraocular Lens

Aug 26

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($168.4M) de RXST superan a sus pasivos a corto plazo ($20.9M).

Pasivo a largo plazo: Los activos a corto plazo de RXST ($168.4M) superan a sus pasivos a largo plazo ($1.3M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: RXST está libre de deudas.

Reducción de la deuda: RXST no tenía deudas hace 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: RXST tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si RXST tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.


Descubre empresas con salud financiera